RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:143

Parathyroid carcinoma

low confidenceDisorder

Query health: suspect — Only one of 2 strategies returned hits (phrase).

Publications

4,020

Trials

7

Interventional, condition-specific

Researchers

1,066

Distinct authors in sample

Gene link

CDC73

Strong

Readiness

3/6

Stages with a signal

Clinical definition (Orphanet)

A rare endocrine tumor characterized by a malignant neoplasm derived from parathyroid parenchymal cells, localized in one of the normally located parathyroid glands or other sites where parathyroid tissue may be present. Signs and symptoms are predominantly due to excess secretion of parathyroid hormone, with marked hypercalcemia and renal and bone involvement. In rare cases, the tumor may be non-functioning and only present as a palpable mass in the neck region. Recurrent laryngeal nerve paralysis is also observed. The tumor can occur sporadically or on a genetic background. The extent of invasion of adjacent structures positively correlates with the development of recurrent or metastatic disease.

How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (12)

adenocarcinoma of parathyroid · adenocarcinoma of parathyroid gland · adenocarcinoma of the parathyroid · adenocarcinoma of the parathyroid gland · carcinoma of parathyroid · carcinoma of parathyroid gland · carcinoma of the parathyroid · carcinoma of the parathyroid gland · parathyroid adenocarcinoma · parathyroid carcinoma · parathyroid gland adenocarcinoma · parathyroid gland carcinoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

3/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedPresent

    Strong — CDC73

  2. LiteraturePresent

    4,020 matched papers (2,195 in last 10 years) Source

  3. Phenotype characterisedNot checked

    Not yet enriched from Monarch / HPO

  4. Animal modelNot checked

    Not yet enriched from Monarch / Alliance

  5. Orphan designationNot checked

    FDA/EMA orphan-drug designation not enriched yet

  6. Interventional trialPresent

    7 matched on ClinicalTrials.gov (2 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Yes — we know a specific gene responsible (CDC73).

GenCC classification: Strong.

Phenotypes (Monarch / HPO)

Not enriched in this build — Monarch phenotype joins were not run for this record.

Animal models (Monarch / Alliance)

Not enriched in this build.

Literature

Is anyone studying this?

4,020

4,020 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.

4,020 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).

2,195 in the last 10 years · low confidence

Phrase hits: 4,020 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,066

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Hu Y10 papers · 2026

    Department of Endocrinology, The Affiliated Hospital of Integrated Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine, Nanjing, China.

    Papers in Europe PMC
  2. 02
    Chen T8 papers · 2026

    Medical Research Center, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  3. 03
    Xiao J8 papers · 2026

    Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  4. 04
    Zheng Q8 papers · 2026

    Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  5. 05
    Cui M6 papers · 2026

    Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  6. 06
    Liao Q6 papers · 2026

    Department of General Surgery, State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China. lqpumc@126.com.

    Papers in Europe PMC
  7. 07
    Wang J6 papers · 2026

    Department of Endocrinology and Metabolism, Tianjin Medical University General Hospital, Tianjin, China, tjmugh.com.cn.

    Papers in Europe PMC
  8. 08
    Wang O6 papers · 2026

    Department of Endocrinology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Translational Medicine Center, Key Laboratory of Endocrinology, Ministry of Health, Beijing, China. wang_ou2010@126.com.

    Papers in Europe PMC
  9. 09
    Wei B6 papers · 2026

    Department of Thyroid and Neck Surgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China. Weibojun1015@126.com.

    Papers in Europe PMC
  10. 10
    Yang S6 papers · 2026

    Department of General Surgery, State Key Laboratory of Complex Severe and Rare Disease, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, 100730, Beijing, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

7

interventional trials for this specific condition

7 interventional trials matched this specific condition name; 2 currently recruiting in our sample.

Data as of 27 July 2026

7 interventional trials — more than 73% of diseases in the trials denominator have none at all (5114 of 7003; this disease is at the 89.9th percentile).

low confidence · 89.9th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

7 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

5 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Where to find support

We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

"Parathyroid carcinoma" OR "adenocarcinoma of parathyroid" OR "adenocarcinoma of the parathyroid" OR "adenocarcinoma of parathyroid gland" OR "adenocarcinoma of the parathyroid gland" OR "carcinoma of parathyroid" OR "carcinoma of the parathyroid" OR "carcinoma of parathyroid gland" OR "carcinoma of the parathyroid gland" OR "parathyroid adenocarcinoma" OR "parathyroid gland adenocarcinoma" OR "parathyroid gland carcinoma"

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"Parathyroid carcinoma" OR "adenocarcinoma of parathyroid" OR "adenocarcinoma of the parathyroid" OR "adenocarcinoma of parathyroid gland" OR "adenocarcinoma of the parathyroid gland" OR "carcinoma of parathyroid" OR "carcinoma of the parathyroid" OR "carcinoma of parathyroid gland" OR "carcinoma of the parathyroid gland" OR "parathyroid adenocarcinoma" OR "parathyroid gland adenocarcinoma" OR "parathyroid gland carcinoma" OR "CDC73"

Recall-expansion terms: CDC73

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 7 interventional · 5 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: suspect — strategies attempted: phrase, recall-expansion; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus
  • Publication count (4020) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity

Ingested 2026-07-26T12:37:53.152Z